Ordóñez Gutiérrez, LaraEspada Fernández, RaquelDea Ayuela, María AuxiliadoraTorrado Durán, Juan JoséBolas Fernández, FranciscoAlunda Rodríguez, José María2024-01-292024-01-292007-10Ordóñez-Gutiérrez L, Espada-Fernández R, Dea-Ayuela MA, Torrado JJ, Bolás-Fernandez F, Alunda JM. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents. 2007 Oct;30(4):325-9. doi: 10.1016/j.ijantimicag.2007.05.013. Epub 2007 Jul 13. PMID: 17631982.0924-857910.1016/j.ijantimicag.2007.05.013https://hdl.handle.net/20.500.14352/95903The in vitro antileishmanial activities of various new amphotericin B (AMB) formulations were investigated, including microspheres of hydrophilic albumin with three AMB aggregation forms (monomeric, dimeric and multiaggregate) and the polymers of polylactic-co-glycolic acid, Resomer RG502 and RG503 with the multiaggregate AMB form. This in vitro study was performed on the extracellular promastigote form and the intracellular amastigote form of a canine strain of Leishmania infantum (UCM 20) using the infected J774 murine macrophage-like cell line. Albumin-encapsulated forms did not show any toxicity for murine cells and had lower median effective concentration (EC50) values (ca. 0.003 microg/mL) for L. infantum amastigotes than free formulations (0.03 microg/mL). In addition, the aggregation state of AMB had a notable effect on the antileishmanial activity of the drug. Results obtained in vitro point towards interest in monomeric AMB encapsulated in microspheres in the chemotherapeutic control of leishmaniasis.engjournal articlehttps://www.sciencedirect.com/science/article/pii/S0924857907002609?via%3Dihubhttps://pubmed.ncbi.nlm.nih.gov/17631982/restricted access616.993.161Amphotericin BIn vitroLeishmania infantumMicroencapsulationAlbuminAmastigoteCiencias24 Ciencias de la Vida